Home

Injection Comité Paragraphe novartis zolgensma press release valeur Courant dominant Se rétracter

Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEO | Fierce Pharma

Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters
Novartis to launch new Zolgensma trial after FDA lifts restriction | Reuters

Novartis faces serious delays in registration of Zolgensma in Russia
Novartis faces serious delays in registration of Zolgensma in Russia

R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence

Zolgensma gene therapy for sma patients: long-term data
Zolgensma gene therapy for sma patients: long-term data

Novartis used faulty data for world's most expensive drug Zolgensma
Novartis used faulty data for world's most expensive drug Zolgensma

Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology
Novartis's SMA gene therapy Zolgensma to be available for NHS use - Pharmaceutical Technology

Novartis allies with Voyager to develop gene therapies in $1.3bn deal
Novartis allies with Voyager to develop gene therapies in $1.3bn deal

Four Takeaways from the Zolgensma Pricing Storm
Four Takeaways from the Zolgensma Pricing Storm

$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian
$2.1m Novartis gene therapy to become world's most expensive drug | Drugs | The Guardian

Novartis Media Release guide - August 2019
Novartis Media Release guide - August 2019

Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma
Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | Fierce Pharma

Novartis releases long-term data for SMA gene therapy
Novartis releases long-term data for SMA gene therapy

Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma
Novartis Lauds Quebec's Move to Reimburse SMA Patients for Zolgensma

Test Achats porte plainte contre un médicament à 2 millions d'euros
Test Achats porte plainte contre un médicament à 2 millions d'euros

Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR
Zolgensma SMA therapy confirms long-term efficacy for up to 7.5 years < Pharma < Article - KBR

Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube
Zolgensma: Progress Report on the World's Most Expensive Drug | The Smart Cube

EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters
EMA seeks to issue guidance on liver damage from Novartis' gene therapy | Reuters

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Novartis Boosts Zolgensma Production Capacity After FDA Clearance
Novartis Boosts Zolgensma Production Capacity After FDA Clearance

R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence
R&D report card: Zolgensma-maker Novartis' spending reaches $9.4B in 2019 | S&P Global Market Intelligence

Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times
Japan's health insurance to cover ¥167 million gene therapy drug - The Japan Times

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)
Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor

ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients
ICNApedia - Zolgensma Benefits Observed in Presymptomatic SMA Patients

Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest
Zolgensma Launch “On Track,” but Significant Challenges Remain - Bionest